France Medical Cannabis Market, by Derivative

Growth Outlook

• The France Medical Cannabis Market, by Derivative market is on a steady long-term growth path. Segment value stands at roughly USD 1083 Mn in 2026 and is projected to reach USD 1474 Mn by 2027 — a gain of about 36% over the forecast period, translating to a CAGR in the double digits.
• What the regional split looks like (2026): Cannabidiol leads, holding roughly 72% of segment value — the single largest regional share. Tetrahydrocannabinol is the second-largest contributor.
• By 2027, Cannabidiol alone is expected to reach USD 1059 Mn, with Tetrahydrocannabinol at USD 415 Mn.

Market Dynamics

France has long been known as a country with strict drug laws, but recent developments in the medical cannabis market signal a shift in attitudes towards the therapeutic use of cannabis. While recreational use of cannabis remains illegal in France, the government has taken steps to legalize medical cannabis and create a legal framework for its production, distribution, and consumption. This move has been driven by the growing demand for alternative forms of treatment for various medical conditions and the potential economic benefits of a regulated medical cannabis market.

One of the main factors driving the demand for medical cannabis in France is the rising awareness of its potential medical benefits. Studies have shown that cannabis can be effective in alleviating symptoms associated with many chronic and debilitating conditions such as multiple sclerosis, epilepsy, and certain types of cancer. As such, many patients are turning to medical cannabis as a supplementary or even primary form of treatment. This has led to a growing demand for cannabis-based medicines and has put pressure on the government to create a legal framework for the production and distribution of these products.

Another driving force behind the increasing demand for medical cannabis in France is the growing support from healthcare professionals. As more international research is conducted on the potential benefits of cannabis, there has been a growing consensus among medical experts that it can be a valuable tool in treating certain conditions. In fact, in 2018, the French National Agency for the Safety of Medicines and Health Products approved the use of a cannabis-based medicine for the treatment of specific forms of severe epilepsy. This has opened the door for other cannabis-based medicines to be developed and prescribed by healthcare professionals, further fueling the demand.

In addition to these factors, the increasing availability and variety of cannabis derivatives also contribute to the demand for medical cannabis in France. While traditional cannabis flower remains illegal, the country has legalized the use of cannabis derivatives such as oils, capsules, and vaporizers for medical purposes. These products offer patients alternative and more discreet ways of consuming cannabis, further driving the demand for medical cannabis in the country.

In conclusion, the demand for medical cannabis in France is on the rise, with patients seeking alternative treatment options and healthcare professionals recognizing its potential benefits. The increasing availability of cannabis derivatives and the government's efforts to create a legal framework for its production and distribution have further fueled this demand. As more research is conducted and attitudes towards cannabis continue to shift, the demand for medical cannabis in France is only expected to increase in the coming years.